eicosapentaenoic acid

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	4.827		Moderate	0.66
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.912		Moderate	0.66
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	8.472	10^-6 cm/s	Moderate	0.66
dh-clint	Dog hepatocyte intrinsic clearance	96.828	uL/min/10^6 cells	Moderate	0.66
dppb	Dog plasma protein binding (% unbound)	0.020	%	Moderate	0.66
fcs-ppb	Fetal calf serum protein binding (% unbound)	0.060	%	Moderate	0.66
herg	hERG pIC50	4.731	pIC50	Moderate	0.66
hh-clint	Human hepatocyte intrinsic clearance	826.038	uL/min/10^6 cells	Moderate	0.66
hlm-clint	Human liver microsomal intrinsic clearance	13.305	uL/min/mg protein	Moderate	0.66
hppb	Human plasma protein binding (% unbound)	0.070	%	Moderate	0.66
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	53
kinase-selectivity-class	AXL,GRK2,MAP2K6,STK33,TEK	5
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.578		Moderate	0.66
mh-clint	Mouse hepatocyte intrinsic clearance	133.660		Moderate	0.66
mppb	Mouse plasma protein binding (% unbound)	0.060		Moderate	0.66
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.803		Moderate	0.66
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	0.030	%	Moderate	0.66
rh-clint	Rat hepatocyte intrinsic clearance	597.035	uL/min/10^6 cells	Moderate	0.66
rh-fuinc	Rat hepatocyte fraction unbound in incubation	2.350	%	Moderate	0.66
rppb	Rat plasma protein binding (% unbound)	0.030	%	Moderate	0.66
solubility-dd	Solubility at pH 7.4 in DMSO	248.313	uM	Moderate	0.66

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Overlap syndrome	159.23	22.20	51	8884	8497	90611015
Drug-induced liver injury	96.12	22.20	76	8859	90242	90529270
Rheumatic disorder	87.44	22.20	26	8909	3382	90616130
Milk-alkali syndrome	86.67	22.20	21	8914	1252	90618260
Hepatic necrosis	86.36	22.20	30	8905	6408	90613104
Blood immunoglobulin M increased	80.08	22.20	20	8915	1352	90618160
Blood immunoglobulin A decreased	75.19	22.20	20	8915	1736	90617776
Blood immunoglobulin G increased	64.78	22.20	20	8915	2952	90616560
Hepatic encephalopathy	64.26	22.20	30	8905	13742	90605770
Condition aggravated	61.73	22.20	162	8773	595383	90024129
Mobility decreased	60.62	22.20	97	8838	250637	90368875
Sciatica	59.48	22.20	61	8874	101321	90518191
Colitis microscopic	57.36	22.20	26	8909	11133	90608379
Type 2 diabetes mellitus	52.39	22.20	81	8854	203163	90416349
Psoriatic arthropathy	52.01	22.20	86	8849	228249	90391263
Hernia	51.34	22.20	26	8909	14205	90605307
Cataract operation	50.51	22.20	20	8915	6143	90613369
Multiple allergies	49.81	22.20	26	8909	15120	90604392
Musculoskeletal pain	49.48	22.20	72	8863	171179	90448333
Hepatic enzyme abnormal	46.35	22.20	20	8915	7622	90611890
Fibromyalgia	46.04	22.20	77	8858	206192	90413320
Prescribed underdose	45.55	22.20	46	8889	74973	90544539
Stomatitis	45.39	22.20	90	8845	274608	90344904
Skin reaction	44.87	22.20	26	8909	18527	90600985
Glaucoma	44.74	22.20	27	8908	20728	90598784
Hypoaesthesia	42.67	22.20	95	8840	314115	90305397
Multiple fractures	42.06	22.20	20	8915	9542	90609970
Hepatotoxicity	41.21	22.20	35	8900	45807	90573705
C-reactive protein increased	39.52	22.20	67	8868	181322	90438190
Maternal exposure during pregnancy	38.26	22.20	99	8836	359964	90259548
Eye disorder	35.61	22.20	26	8909	27364	90592148
Hepatic cirrhosis	35.17	22.20	37	8898	63216	90556296
Osteoarthritis	34.58	22.20	66	8869	195664	90423848
Lip dry	34.44	22.20	46	8889	100909	90518603
Nail disorder	31.86	22.20	34	8901	59033	90560479
Helicobacter infection	31.22	22.20	69	8866	226781	90392731
Urticaria	31.18	22.20	84	8851	312650	90306862
Adverse event	30.50	22.20	47	8888	117371	90502141
C-reactive protein	30.37	22.20	25	8910	31342	90588170
Diverticulitis	29.81	22.20	29	8906	45158	90574354
Breast cancer stage III	29.60	22.20	39	8896	84408	90535104
Road traffic accident	29.26	22.20	44	8891	107582	90511930
Rheumatoid arthritis	29.01	22.20	90	8845	362524	90256988
Immunodeficiency	29	22.20	28	8907	43206	90576306
Nasopharyngitis	28.91	22.20	97	8838	407007	90212505
Epilepsy	28.87	22.20	38	8897	82168	90537344
Pain	28.39	22.20	34	8901	996307	89623205
Wound infection	28.21	22.20	43	8892	106359	90513153
Nausea	27.49	22.20	42	8893	1110274	89509238
Muscle injury	26.91	22.20	56	8879	176598	90442914
Drug resistance	26.86	22.20	23	8912	30426	90589086
Sinusitis	26.38	22.20	84	8851	343004	90276508
Live birth	25.39	22.20	35	8900	79072	90540440
Obesity	24.33	22.20	40	8895	105467	90514045
Facet joint syndrome	23.63	22.20	38	8897	98351	90521161
Blood creatine phosphokinase MM increased	23.50	22.20	4	8931	38	90619474
Sleep disorder due to general medical condition, insomnia type	23.46	22.20	44	8891	128650	90490862
Calculus urinary	23.11	22.20	8	8927	1690	90617822
Red blood cell sedimentation rate increased	22.77	22.20	34	8901	82561	90536951
Liver injury	22.47	22.20	51	8884	170516	90448996

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine albumin/creatinine ratio decreased	43.71	23.52	6	1610	34	42619685
Cerebral infarction	35.05	23.52	19	1597	31150	42588569
Interstitial lung disease	29.22	23.52	24	1592	78438	42541281
Diabetes mellitus	25.82	23.52	20	1596	60067	42559652
Immunosuppressant drug level increased	25.62	23.52	10	1606	7721	42611998
Hepatic function abnormal	23.99	23.52	18	1598	51549	42568170

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Overlap syndrome	165.27	19.09	52	9854	9007	110570386
Drug-induced liver injury	89.52	19.09	79	9827	119988	110459405
Rheumatic disorder	88.56	19.09	26	9880	3565	110575828
Milk-alkali syndrome	79.19	19.09	21	9885	1984	110577409
Blood immunoglobulin M increased	78.48	19.09	20	9886	1617	110577776
Hepatic necrosis	76.51	19.09	30	9876	9892	110569501
Blood immunoglobulin A decreased	72.19	19.09	20	9886	2228	110577165
Sciatica	65.29	19.09	59	9847	92340	110487053
Blood immunoglobulin G increased	61.79	19.09	20	9886	3788	110575605
Maternal exposure during pregnancy	60.70	19.09	93	9813	254790	110324603
Mobility decreased	59.90	19.09	89	9817	237333	110342060
Colitis microscopic	58.30	19.09	27	9879	13367	110566026
Multiple allergies	57.40	19.09	26	9880	12237	110567156
Cataract operation	56.94	19.09	21	9885	5862	110573531
Type 2 diabetes mellitus	54.42	19.09	73	9833	177159	110402234
Psoriatic arthropathy	54.34	19.09	77	9829	196684	110382709
Musculoskeletal pain	54.09	19.09	74	9832	182949	110396444
Hepatic encephalopathy	51.76	19.09	32	9874	28224	110551169
Fibromyalgia	50.35	19.09	69	9837	170840	110408553
Hypoaesthesia	48.94	19.09	95	9811	314128	110265265
Condition aggravated	48.39	19.09	160	9746	734676	109844717
Osteoarthritis	48.27	19.09	70	9836	182553	110396840
Glaucoma	47.71	19.09	28	9878	22489	110556904
Hepatic enzyme abnormal	46.65	19.09	21	9885	9742	110569651
Stomatitis	46.16	19.09	85	9821	270157	110309236
Hernia	45.99	19.09	26	9880	19474	110559919
Multiple fractures	45.18	19.09	20	9886	8920	110570473
Skin reaction	44.03	19.09	26	9880	21118	110558275
Hepatic cirrhosis	41.62	19.09	40	9866	67586	110511807
Rheumatoid arthritis	41.17	19.09	86	9820	299527	110279866
Lip dry	39.91	19.09	47	9859	100036	110479357
Prescribed underdose	39.07	19.09	38	9868	65136	110514257
Helicobacter infection	38.61	19.09	63	9843	181814	110397579
Wound infection	37.97	19.09	45	9861	96420	110482973
Nail disorder	37.04	19.09	35	9871	57900	110521493
Eye disorder	36.59	19.09	26	9880	28880	110550513
C-reactive protein increased	36.51	19.09	68	9838	217851	110361542
Nasopharyngitis	36.50	19.09	97	9809	394264	110185129
Breast cancer stage III	36.37	19.09	40	9866	79077	110500316
Hepatotoxicity	34.37	19.09	35	9871	63365	110516028
Immunodeficiency	33.90	19.09	28	9878	38810	110540583
C-reactive protein	33.23	19.09	25	9881	30306	110549087
Muscle injury	32.94	19.09	51	9855	140756	110438637
Toxicity to various agents	32.14	19.09	3	9903	480552	110098841
Diverticulitis	31.69	19.09	31	9875	53491	110525902
Urticaria	31.09	19.09	80	9826	318777	110260616
Sinusitis	30.56	19.09	76	9830	296612	110282781
Epilepsy	30.31	19.09	41	9865	100168	110479225
Sleep disorder due to general medical condition, insomnia type	30.11	19.09	42	9864	105601	110473792
Road traffic accident	29.57	19.09	42	9864	107356	110472037
Obesity	29.27	19.09	43	9863	113308	110466085
Cerebral infarction	28.80	19.09	29	9877	51809	110527584
Facet joint syndrome	28.35	19.09	39	9867	96789	110482604
Nausea	28.23	19.09	42	9864	1235648	109343745
Cataract	26.32	19.09	34	9872	79451	110499942
Adverse event	26.27	19.09	40	9866	108769	110470624
Pain	25.33	19.09	29	9877	954926	109624467
Red blood cell sedimentation rate increased	25.15	19.09	33	9873	78269	110501124
Live birth	25.03	19.09	31	9875	69453	110509940
Blood creatine phosphokinase MM increased	23.61	19.09	4	9902	41	110579352
Neutropenia	23.36	19.09	3	9903	374617	110204776
Arthropathy	20.09	19.09	64	9842	287458	110291935
Swelling	20.02	19.09	73	9833	350968	110228425
C-reactive protein abnormal	19.89	19.09	39	9867	129656	110449737

Source	Code	Description
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35821	anticholesteremic drugs
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76946	fungal metabolites
CHEBI has role	CHEBI:83038	Daphnia galeata metabolites
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:76507	marine metabolites

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

eicosapentaenoic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
Pregnancy, function	indication	289908002
Breastfeeding (mother)	indication	413712001
Hypertriglyceridemia	off-label use	302870006
Myocardial Reinfarction Prevention	off-label use
Prevention of Fetal Neural Tube Defects during Pregnancy	off-label use
Arteriosclerotic Vascular Disease Prevention	off-label use
Peptic ulcer	contraindication	13200003	DOID:750
Bipolar disorder	contraindication	13746004	DOID:3312
Gastroenteritis	contraindication	25374005	DOID:2326
Hemosiderosis	contraindication	39011001	DOID:12119
Hypokalemia	contraindication	43339004
Gastrectomy	contraindication	53442002
Leber's optic atrophy	contraindication	58610003	DOID:705
Hemolytic anemia	contraindication	61261009	DOID:583
Ulcerative colitis	contraindication	64766004	DOID:8577
Diabetes mellitus	contraindication	73211009	DOID:9351
Phototoxicity	contraindication	84326006
Atrophic gastritis	contraindication	84568007	DOID:8929
Hypomania	contraindication	231496004
Diverticular disease	contraindication	397881000
Hemochromatosis	contraindication	399187006	DOID:2352
Repeated Blood Transfusions	contraindication

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Aromatase	Enzyme	P11511	CP19A_HUMAN	IC50	4.27	CHEMBL
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN	IC50	5.96	CHEMBL
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN	Kd	5.70	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN	Ki	5.12	CHEMBL
Peroxisome proliferator-activated receptor delta	Nuclear hormone receptor	Q03181	PPARD_HUMAN	IC50	5.40	CHEMBL
Tissue factor	Membrane receptor	P13726	TF_HUMAN	IC50	4.11	CHEMBL
Oxoeicosanoid receptor 1	GPCR	Q8TDS5	OXER1_HUMAN	IC50	5.70	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_SHEEP	IC50	5.15	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_BOVIN	IC50	4.89	CHEMBL

ID	Source
4020139	VUID
N0000148114	NUI
D08061	KEGG_DRUG
4020139	VANDF
C0000545	UMLSCUI
CHEBI:28364	CHEBI
EPA	PDB_CHEM_ID
CHEMBL460026	ChEMBL_ID
DB00159	DRUGBANK_ID
D015118	MESH_DESCRIPTOR_UI
5282847	PUBCHEM_CID
90	RXNORM
d07891	MMSL
002052	NDDF
226367006	SNOMEDCT_US
763707009	SNOMEDCT_US
7441	IUPHAR_LIGAND_ID
6328	INN_ID
AAN7QOV9EA	UNII
AAN7QOV9EA	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TriStart DHA	HUMAN PRESCRIPTION DRUG LABEL	15	15370-250	CAPSULE, LIQUID FILLED	15 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
BP Vit 3	HUMAN PRESCRIPTION DRUG LABEL	7	42192-301	CAPSULE, COATED	35 mg	ORAL	unapproved drug other	7 sections
PNV-Omega	HUMAN PRESCRIPTION DRUG LABEL	13	42192-332	CAPSULE, GELATIN COATED	40 mg	ORAL	unapproved drug other	12 sections
Animi-3 with Vitamin D	HUMAN PRESCRIPTION DRUG LABEL	8	66213-542	CAPSULE	35 mg	ORAL	unapproved drug other	14 sections
Animi-3	HUMAN PRESCRIPTION DRUG LABEL	8	66213-543	CAPSULE	35 mg	ORAL	unapproved drug other	14 sections
Prenate Essential	HUMAN PRESCRIPTION DRUG LABEL	14	75854-313	CAPSULE, GELATIN COATED	40 mg	ORAL	unapproved drug other	13 sections
SOUTH MOON Propolis Professional Treatment Gel	HUMAN OTC DRUG LABEL	4	84660-034	GEL	3 g	TOPICAL	OTC Monograph Drug	8 sections